ContributorsPublishersAdvertisers

Dr. Kopetz on the Rationale for the BREAKWATER Trial in BRAF V600E-Mutant mCRC

onclive.com
 2022-01-20

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer. Edmund Scott Kopetz, MD, PhD, FACP, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson...

www.onclive.com

Comments / 0

Comments / 0